Literature DB >> 22283603

Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

James W Hodge1, Hadley J Sharp, Sofia R Gameiro.   

Abstract

Radiation is a primary modality in cancer treatment. Radiation can also reduce tumor growth outside the treatment field, often referred to as the abscopal effect. The mechanisms and therapeutic potential of the abscopal effect have not been fully elucidated. We evaluated the role of vaccination directed against a tumor-associated antigen (TAA) in the induction and amplification of radiation induced abscopal effects. Active-specific immunotherapy with a TAA-specific vaccine regimen was used to induce and potentiate T-cell responses against carcinoembryonic antigen (CEA) in combination with local irradiation of subcutaneous tumors. We examined the potential synergy of a poxvirus-based CEA vaccine regimen in CEA-transgenic (Tg) mice in combination with either external beam radiation or brachytherapy of local tumors. The induction of CD8(+) T cells specific for multiple TAAs not encoded by the vaccine was observed after the combination therapy. In two tumor models, the antigen cascade responses induced by vaccine and local irradiation mediated the regression of antigen negative metastases at distal subcutaneous or pulmonary sites. Clinically, local control of the primary tumor is necessary and can sometimes prevent metastases; however, irradiation generally fails to control preexisting metastases. These studies suggest that by coupling tumor irradiation with immunotherapy, the abscopal effect can transcend from anecdotal observation to a defined mechanism that can be exploited for the treatment of systemic disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22283603      PMCID: PMC3277931          DOI: 10.1089/cbr.2012.1202

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  45 in total

1.  Whole body irradiation; radiobiology or medicine?

Authors:  R H MOLE
Journal:  Br J Radiol       Date:  1953-05       Impact factor: 3.039

2.  Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis.

Authors:  K Ohba; K Omagari; T Nakamura; N Ikuno; S Saeki; I Matsuo; H Kinoshita; J Masuda; H Hazama; I Sakamoto; S Kohno
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

3.  A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.

Authors:  V Lacabanne; M Viguier; J G Guillet; J Choppin
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

4.  Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.

Authors:  J W Hodge; J P McLaughlin; J A Kantor; J Schlom
Journal:  Vaccine       Date:  1997 Apr-May       Impact factor: 3.641

Review 5.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

Authors:  M Lenardo; K M Chan; F Hornung; H McFarland; R Siegel; J Wang; L Zheng
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

Review 6.  The controversial abscopal effect.

Authors:  Joseph M Kaminski; Eric Shinohara; James Bradley Summers; Kenneth J Niermann; Allan Morimoto; Jeffrey Brousal
Journal:  Cancer Treat Rev       Date:  2005-05       Impact factor: 12.111

7.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

8.  Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.

Authors:  Charlie T Garnett; Claudia Palena; Mala Chakraborty; Mala Chakarborty; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

9.  Irradiation induces upregulation of CD31 in human endothelial cells.

Authors:  S Quarmby; P Kumar; J Wang; J A Macro; J J Hutchinson; R D Hunter; S Kumar
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

Review 10.  Mechanisms of peripheral T cell tolerance.

Authors:  L van Parijs; V L Perez; A K Abbas
Journal:  Novartis Found Symp       Date:  1998
View more
  52 in total

1.  Is the induction of tumor cell senescence the key to a good irradiated tumor vaccine?

Authors:  Michael P Brown
Journal:  Mol Ther       Date:  2012-05       Impact factor: 11.454

Review 2.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

3.  Therapeutic vaccines: the ultimate personalized therapy?

Authors:  James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

4.  PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Authors:  Megan Morisada; Paul E Clavijo; Ellen Moore; Lillian Sun; Michael Chamberlin; Carter Van Waes; James W Hodge; James B Mitchell; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

5.  Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Authors:  James L Gulley; Ravi A Madan; Kwong Y Tsang; Caroline Jochems; Jennifer L Marté; Benedetto Farsaci; Jo A Tucker; James W Hodge; David J Liewehr; Seth M Steinberg; Christopher R Heery; Jeffrey Schlom
Journal:  Cancer Immunol Res       Date:  2013-11-04       Impact factor: 11.151

6.  Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Authors:  Andressa Ardiani; Benedetto Farsaci; Connie J Rogers; Andy Protter; Zhimin Guo; Thomas H King; David Apelian; James W Hodge
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

Review 7.  Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Authors:  Charlie Garnett-Benson; James W Hodge; Sofia R Gameiro
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 8.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

Review 9.  Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.

Authors:  Eric D Brooks; Jonathan E Schoenhals; Chad Tang; Goran Micevic; Daniel R Gomez; Joe Y Chang; James W Welsh
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

Review 10.  Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.

Authors:  Max M Wattenberg; Ahmed Fahim; Mansoor M Ahmed; James W Hodge
Journal:  Radiat Res       Date:  2014-06-24       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.